(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
‘The White Lotus’ sparked online interest in risky anxiety pills, study says - 2Believe Should Unwind? Look at These Scaled down Games
- 3How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- 4The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- 5Italy now recognizes the crime of femicide and punishes it with life in prison
- 5 VIPs That Changed Style
- The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
- Flu illness count nears 5 million, with New York City among the hardest hit
- Washington resident contracts bird flu, first human case in U.S. since February
- ‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- 6 Asian Urban areas to Visit
- Pick Your Number one breakfast food
